<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="52650"><DrugName>AEZS-127</DrugName><DrugSynonyms><Name><Value>erucylphosphocholine</Value></Name><Name><Value>ErPC</Value></Name><Name><Value>ZEN-027</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>AEZS-127</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="22711">AEterna Zentaris Inc</CompanyOriginator><CompaniesSecondary><Company id="22711">AEterna Zentaris Inc</Company><Company id="27395">Keryx Biopharmaceuticals Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="52650" type="Drug"><TargetEntity id="226662" type="siDrug">Erucylphosphocholine</TargetEntity></SourceEntity><SourceEntity id="22711" type="Company"><TargetEntity id="4295862603" type="organizationId">Aeterna Zentaris Inc</TargetEntity></SourceEntity><SourceEntity id="27395" type="Company"><TargetEntity id="4295900456" type="organizationId">Keryx Biopharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity><SourceEntity id="1589" type="Action"><TargetEntity id="1062" type="Mechanism">Apoptosis Inducers</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="651">Cancer</Indication></IndicationsSecondary><ActionsPrimary><Action id="7025">Signal transduction inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1589">Apoptosis stimulator</Action><Action id="1545">Anticancer</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="648">Intravenous formulation</Technology></Technologies><LastModificationDate>2017-08-24T03:44:36.000Z</LastModificationDate><ChangeDateLast>2012-07-20T00:00:00.000Z</ChangeDateLast><AddedDate>2005-01-07T15:23:45.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="22711" linkType="Company"&gt;AEterna Zentaris&lt;/ulink&gt; was investigating AEZS-127 (ZEN-027, erucylphosphocholine; ErPC), an analog of &lt;ulink linkID="7711" linkType="Drug"&gt;perifosine&lt;/ulink&gt; and an alkylphosphocholine that disrupts membrane signalling primarily in proliferating cells and stimulates apoptosis, for the potential iv treatment of cancer  [&lt;ulink linkID="578527" linkType="Reference"&gt;&lt;/ulink&gt;&lt;ulink linkID="578527" linkType="Reference"&gt;578527&lt;/ulink&gt;]. By January 2005, preclinical studies had begun [&lt;ulink linkID="578527" linkType="Reference"&gt;578527&lt;/ulink&gt;]; in December 2011, the drug was listed as being in preclinical development [&lt;ulink linkID="1247919" linkType="Reference"&gt;1247919&lt;/ulink&gt;]. This was still the case in July 2012 [&lt;ulink linkID="1308847" linkType="Reference"&gt;1308847&lt;/ulink&gt;], however, later that month, the drug was no longer listed on the company's pipeline [&lt;ulink linkID="1309883" linkType="Reference"&gt;1309883&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="27395" linkType="Company"&gt;Keryx&lt;/ulink&gt;, in collaboration with  AEterna,  was previously investigating AEZS-127 for cancer. However, by March 2010, AEterna  had stated that it had worldwide rights to the program [&lt;ulink linkID="1085288" linkType="Reference"&gt;1085288&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By March 2010, in tumor cells, AEZS-127 had demonstrated  induction of programmed cell death and it interfered primarily with membranes of proliferating cells. The drug inhibited Akt- and Raf/MEK/ERK- mediated signalling [&lt;ulink linkID="1085288" linkType="Reference"&gt;1085288&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="27395">Keryx Biopharmaceuticals Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="651">Cancer</Indication><StatusDate>2010-03-25T00:00:00.000Z</StatusDate><Source id="1085288" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27395">Keryx Biopharmaceuticals Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="651">Cancer</Indication><StatusDate>2010-03-25T00:00:00.000Z</StatusDate><Source id="1085288" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27395">Keryx Biopharmaceuticals Inc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="651">Cancer</Indication><StatusDate>2010-03-25T00:00:00.000Z</StatusDate><Source id="1085288" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27395">Keryx Biopharmaceuticals Inc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="651">Cancer</Indication><StatusDate>2010-03-25T00:00:00.000Z</StatusDate><Source id="1085288" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27395">Keryx Biopharmaceuticals Inc</Company><Country id="XD">North America</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="651">Cancer</Indication><StatusDate>2010-03-25T00:00:00.000Z</StatusDate><Source id="1085288" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22711">AEterna Zentaris Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2012-07-20T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="22711">AEterna Zentaris Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2005-01-06T00:00:00.000Z</StatusDate><Source id="578527" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27395">Keryx Biopharmaceuticals Inc</Company><Country id="XD">North America</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2005-01-06T00:00:00.000Z</StatusDate><Source id="578527" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27395">Keryx Biopharmaceuticals Inc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2005-01-06T00:00:00.000Z</StatusDate><Source id="578527" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27395">Keryx Biopharmaceuticals Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2005-01-06T00:00:00.000Z</StatusDate><Source id="578527" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27395">Keryx Biopharmaceuticals Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2005-01-06T00:00:00.000Z</StatusDate><Source id="578527" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27395">Keryx Biopharmaceuticals Inc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2005-01-06T00:00:00.000Z</StatusDate><Source id="578527" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-02016"><Name>Signal transduction</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1039441">Akebia Therapeutics Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="22711">AEterna Zentaris Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="107568" title="Keryx Biopharmaceuticals to develop AEterna Zentaris' Erucylphosphocholine in North America, South Africa, Israel, Australia and New Zealand "/></Deals><hasSWOTs>N</hasSWOTs></drugRecordOutput>